Targeted Oncology12d
LYT-200 Gains FDA Fast Track Status in Acute Myeloid Leukemia
LYT-200 now has gained fast track designation from the FDA in acute myeloid leukemia in addition to its prior designation for ...
Morningstar17d
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
Single agent and combination data from Phase 1b AML/MDS trial presented at ASH 2024 showed potential of LYT-200 to serve broad range of patients across various lines of treatment LYT-200 is ...
London South East17d
PureTech receives FDA fast track designation for leukemia treatment
(Alliance News) - PureTech Health PLC on Thursday said that the US Food & Drug Administration has granted fast track designation to its antibody LYT-200 for the treatment of acute myeloid leukemia.
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
LYT-200 exerts its therapeutic effects in AML by killing cancer cells directly via apoptosis and DNA damage as well as reactivating central anti-cancer effectors of the immune system. LYT-200 is the ...